SCHEMBL4864398

SCHEMBL4864398

OCCNc1nc(-c2ccc(Cl)cc2)nc2ccccc12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.85
KMT2A Q03164 3/20 0.85
MAPK1 P28482 3/20 0.80
POLB P06746 2/20 0.72
SLC2A1 P11166 1/20 0.69
PDE10A Q9Y233 1/20 0.67
PDE5A O76074 5/20 0.66
ALDH1A1 P00352 1/20 0.65
LMNA P02545 1/20 0.65
HPGD P15428 1/20 0.65
MAPT P10636 4/20 0.63
TSHR P16473 1/20 0.63
TP53 P04637 2/20 0.62
NPSR1 Q6W5P4 1/20 0.60
GAA P10253 1/20 0.60
GBA1 P04062 1/20 0.60
ABCG2 Q9UNQ0 1/20 0.59
SIRT5 Q9NXA8 1/20 0.59
ACP1 P24666 1/20 0.58
TLR9 Q9NR96 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868364 0.88 MEN1 (0.74) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL16217089 0.86 PDE5A (0.82) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL16404321 0.85 MAPK1 (0.82) MEN1KMT2AMAPK1POLBPDE5A
SCHEMBL4868215 0.85 PDE5A (0.82) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL3459468 0.85 MAPK1 (0.82) MEN1KMT2AMAPK1POLBPDE5A
SCHEMBL14758284 0.83 POLB (0.86) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL4868103 0.83 PDE5A (0.82) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL2583256 0.82 PDE5A (0.90) MEN1KMT2AMAPK1POLBPDE10A
SCHEMBL4864232 0.82 MEN1 (0.74) MEN1KMT2AMAPK1POLBSLC2A1
SCHEMBL1083850 0.82 MAPT (0.69) MEN1KMT2AMAPK1POLBSLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MEN1 3837/4885KMT2A 1662/4885MAPK1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.